ArticleBiological trace element research2026
Supranutritional Selenomethionine but not Selenite Reduces Malignant Cell Transformation.
Article in Biological trace element research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The trace element selenium is essential to human health and has long been discussed to modulate the carcinogenic process. So far, the functions of selenium and selenoproteins have been mainly studied in already transformed cancer cells. The aim of this study was, therefore, to characterize the role of selenium during the neoplastic transformation process in a concentration- and species-specific manner using the BALB/c cell transformation assay. This assay mimics the initiation and promotion phase of BALB/c cells (murine fibroblasts) treated with a tumor initiator (MCA) and promoter (TPA) leading to malignant cell foci development. In parallel, cells were supplied with selenite or selenomethionine using suboptimal, adequate or supranutritional concentrations (0.01-1 μM). The supranutritional selenomethionine concentration reduced malignantly transformed foci, accompanied by higher NQO1 levels suggesting an upregulation of antioxidant NRF2 target genes. In contrast, treatment with the same concentration of selenite appeared to increase malignant transformation which was associated with higher intracellular selenium concentrations. Neither suboptimal nor adequate concentrations of either selenium species affected malignant cell transformation even though selenoprotein expression was modulated. Overall, the current data suggest that high concentrations of selenium have different effects on malignant cell transformation depending on the distinct selenium species applied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.